Authorization

Micellae Delivery Systems Appoints Dr. Andrew Kerklaan as CEO

TORONTO, Aug. 10, 2022 /PRNewswire/ - Micellae Delivery Systems Inc. ("Micellae"), the provider of best-in-class solubility and bioavailability-enhancing technology for cannabinoids, is pleased to announce the appointment of Dr. Andrew Kerklaan as the Company's new Chief Executive Officer.
Micellae Delivery Systems Appoints Dr. Andrew Kerklaan as CEO
Dr. Kerklaan takes over from Dr. Mehdi Nouraei, Micellae's founder, who will now focus on his roles as Chief Science Officer and Chairman of the Board. "We have enjoyed significant growth in the last 12 months, and it is now time for an experienced industry CEO to accelerate our expansion into the US and other international markets, while strengthening Micellae's R&D and commercial activities in Canada," said Dr. Nouraei. "Andrew has an impressive track record; we are delighted to welcome him to the team," Dr. Nouraei added. Dr. Kerklaan is a pioneer in the cannabis sector, who has brought to market many health-focused cannabinoid products. He founded Dr. Kerklaan Therapeutics, a premium brand built on a deep understanding of patient needs and the health benefits of cannabinoids. He has been involved in all aspects of cannabis product development, manufacturing, and marketing, including the launch of oil extraction and refinement facilities in California and Oregon, the development and formulation of unique products, and the retail of finished products in global markets."Dr. Nouraei and the leadership team have built a very solid foundation for the continued growth and success of Micellae which now sits at the forefront of cannabis product innovation with its patent pending technology, and I am proud to be joining the team at this time," said Dr. Kerklaan. "Micellae's approach of developing a data-focused science-first foundation is having a huge impact on improving cannabis product effectiveness. The industry is at a critical stage where product formulations must improve upon the known issues of unpredictable onset times and inconsistent effects. Micellae's O2W technology is achieving this, delivering best-in-class standards for enhancing solubility and bioavailability," added Dr. Kerklaan.
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Октябрь 2022    »
ПнВтСрЧтПтСбВс
 12
3456789
10111213141516
17181920212223
24252627282930
31